945976-76-1

945976-76-1 structure

Name: LX-1031
Chemical Name: (2S)-2-amino-3-[4-[2-amino-6-[(1R)-2,2,2-trifluoro-1-[4-(3-methoxyphenyl)phenyl]ethoxy]pyrimidin-4-yl]phenyl]propanoic acid
CAS Number: 945976-76-1
Molecular Formula: C₂₈H₂₅F₃N₄O₄
Molecular Weight: 538.518
Catalog: Biochemical Amino acids and their derivatives Phenylalanine derivatives
Create Date: 2017-06-06 11:39:11
Modify Date: 2025-08-26 12:19:33
LX-1031 is a potent, orally available tryptophan 5-hydroxylase (TPH) inhibitor that reduces serotonin (5-HT) synthesis peripherally.

Name	(2S)-2-amino-3-[4-[2-amino-6-[(1R)-2,2,2-trifluoro-1-[4-(3-methoxyphenyl)phenyl]ethoxy]pyrimidin-4-yl]phenyl]propanoic acid
Synonyms	unii-j08e1j78gk 4-{2-Amino-6-[(1R)-2,2,2-trifluoro-1-(3'-methoxy-4-biphenylyl)ethoxy]-4-pyrimidinyl}-L-phenylalanine cs-0452 lx-1031 lx-1031\|\|lx 1031 L-Phenylalanine, 4-[2-amino-6-[(1R)-2,2,2-trifluoro-1-(3'-methoxy[1,1'-biphenyl]-4-yl)ethoxy]-4-pyrimidinyl]-

Description	LX-1031 is a potent, orally available tryptophan 5-hydroxylase (TPH) inhibitor that reduces serotonin (5-HT) synthesis peripherally.
Related Catalog	Signaling Pathways >> Metabolic Enzyme/Protease >> Tryptophan Hydroxylase Research Areas >> Neurological Disease
In Vivo	With oral administration of LX-1031 in mice, the average 5-HT reductions in the jejunum relative to control are appr 33, 51, and 66% with the 15, 45 and 135 mg/kg/day doses respectively. In a preliminary report, the effects of LX-1031, 100 mg/kg daily, on 5-HT levels in jejunal mucosa are reversible within 2 days of discontinuation in mice[1]. LX-1031 dose-dependently reduces expression of 5-HT in the duodenum, jejunum and ileum, but has no effect on brain 5-HT levels in preclinical assay[2].
References	[1]. Camilleri M. LX-1031, a tryptophan 5-hydroxylase inhibitor, and its potential in chronic diarrhea associated with increased serotonin. Neurogastroenterol Motil. 2011 Mar;23(3):193-200. [2]. Camilleri M. LX-1031, a tryptophan 5-hydroxylase inhibitor that reduces 5-HT levels for the potential treatment of irritable bowel syndrome. IDrugs. 2010 Dec;13(12):921-8.